Tolerability issues for selpercatinib that can lead to dose reductions or discontinuations include the following: hepatotoxicity (ALT/AST increases); interstitial lung disease/pneumonitis; hypertension; QTc interval prolongation; hemorrhagic events; hypersensitivity; tumor lysis syndrome; or hypothyroidism [18]. This evidence concerns the gene GPT and hypertensive disorder.